ETF Holdings Breakdown of EXEL

EXEL institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-18	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	333,738	USD 13,499,702 0.0%
2025-09-18	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	160,538 0.3%	USD 6,493,762 0.3%
2025-09-18	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	160,538 0.3%	USD 6,493,762 0.3%
2025-09-18	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	3,324	USD 134,456 0.0%
Total =		658,138	USD 26,621,682

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with EXEL

Exelixis (NASDAQ:EXEL) Price Target Raised to $50.00 at Morgan Stanley

Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective lifted by investment analysts at Morgan Stanley from $46.00 to $50.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 23.61% from the company’s […] - 2025-09-19 02:36:46

Exelixis (NASDAQ:EXEL) Rating Increased to Hold at Barclays

Barclays upgraded shares of Exelixis (NASDAQ:EXEL – Free Report) to a hold rating in a research report report published on Tuesday morning,Zacks.com reports. A number of other analysts also recently weighed in on the company. Bank of America lifted their price target on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating […] - 2025-09-19 02:02:49

Exelixis (NASDAQ:EXEL) Rating Lowered to “Hold” at Wall Street Zen

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday. Several other equities analysts have also recently issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Exelixis in a […] - 2025-09-15 02:06:56

Zacks Research Predicts Exelixis’ Q3 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Research analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Exelixis in a research report issued on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.62 per share for the quarter, down from their previous estimate of […] - 2025-09-01 02:44:58

Exelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of “Moderate Buy” from Analysts

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and thirteen have assigned a buy recommendation to the […] - 2025-08-18 05:10:57

Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by LPL Financial LLC

LPL Financial LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 74.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,097 shares of the biotechnology company’s stock after purchasing an additional 79,885 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-11 05:34:56

Exelixis, Inc. (NASDAQ:EXEL) Position Increased by Natixis Advisors LLC

Natixis Advisors LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 14.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,922 shares of the biotechnology company’s stock after purchasing an additional 9,072 shares during the period. […] - 2025-08-08 05:18:54

Wall Street Zen Downgrades Exelixis (NASDAQ:EXEL) to Buy

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Several other equities analysts also recently commented on the stock. HC Wainwright upped their price target on shares of Exelixis from $47.00 to $53.00 […] - 2025-08-04 04:27:00

Exelixis (NASDAQ:EXEL) Given “Market Outperform” Rating at JMP Securities

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock. JMP Securities’ price objective would suggest a potential upside of 35.69% […] - 2025-07-31 04:18:47

Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03

Truist Financial Has Lowered Expectations for Exelixis (NASDAQ:EXEL) Stock Price

Exelixis (NASDAQ:EXEL – Free Report) had its price objective trimmed by Truist Financial from $56.00 to $49.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also recently weighed in on EXEL. Benchmark reiterated a “neutral” rating […] - 2025-07-30 06:13:05

Exelixis (NASDAQ:EXEL) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on Tuesday morning,RTT News reports. Several other analysts also recently commented on EXEL. Wells Fargo & Company reiterated a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Jefferies Financial […] - 2025-07-30 04:54:52

Exelixis (NASDAQ:EXEL) Given New $45.00 Price Target at Royal Bank Of Canada

Exelixis (NASDAQ:EXEL – Free Report) had its target price cut by Royal Bank Of Canada from $50.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock. EXEL has been the subject of several other research reports. Truist Financial boosted their target […] - 2025-07-30 04:54:49

Morgan Stanley Cuts Exelixis (NASDAQ:EXEL) Price Target to $46.00

Exelixis (NASDAQ:EXEL – Free Report) had its target price decreased by Morgan Stanley from $48.00 to $46.00 in a report released on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. EXEL has been the subject of several other reports. Stephens upgraded Exelixis from an “equal weight” rating to […] - 2025-07-30 04:20:59

Exelixis Target of Unusually Large Options Trading (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 12,250 call options on the stock. This is an increase of 373% compared to the typical volume of 2,588 call options. Wall Street Analysts Forecast Growth Several brokerages have issued reports on EXEL. Morgan […] - 2025-07-30 03:07:01

Exelixis (NASDAQ:EXEL) Shares Gap Down on Analyst Downgrade

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s share price gapped down before the market opened on Tuesday after Truist Financial lowered their price target on the stock from $56.00 to $49.00. The stock had previously closed at $44.39, but opened at $38.26. Truist Financial currently has a buy rating on the stock. Exelixis shares last […] - 2025-07-30 03:06:57

Arizona State Retirement System Sells 790 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Arizona State Retirement System trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,696 shares of the biotechnology company’s stock after selling 790 shares during the period. Arizona […] - 2025-07-17 06:56:52

Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Cerity Partners LLC

Cerity Partners LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 127.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,915 shares of the biotechnology company’s stock after purchasing an additional 94,031 shares during the quarter. Cerity Partners LLC owned […] - 2025-07-16 06:51:24

Exelixis, Inc. (NASDAQ:EXEL) Holdings Reduced by Alps Advisors Inc.

Alps Advisors Inc. decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,709 shares of the biotechnology company’s stock after selling 3,291 shares during the period. Alps Advisors Inc.’s holdings […] - 2025-07-16 05:23:13

Bank of New York Mellon Corp Grows Position in Exelixis, Inc. (NASDAQ:EXEL)

Bank of New York Mellon Corp lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,476,857 shares of the biotechnology company’s stock after purchasing an additional 15,239 shares during the quarter. Bank […] - 2025-07-11 06:13:00

Principal Financial Group Inc. Sells 14,218 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 648,218 shares of the biotechnology company’s stock after selling 14,218 shares during the period. Principal Financial Group Inc. owned approximately 0.24% […] - 2025-07-09 05:51:35

Traders Buy Large Volume of Call Options on Exelixis (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders purchased 3,495 call options on the stock. This is an increase of 56% compared to the typical daily volume of 2,238 call options. Insider Activity In other Exelixis news, Director Sue Gail Eckhardt sold 18,838 shares […] - 2025-07-09 02:50:45

Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 12.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 359,105 shares of the biotechnology company’s stock after selling 52,707 shares during the period. New York State Teachers Retirement […] - 2025-07-04 05:31:06

HC Wainwright Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock

Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective hoisted by research analysts at HC Wainwright from $47.00 to $53.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 21.50% from […] - 2025-07-02 03:02:56

Bartlett & CO. Wealth Management LLC Makes New $37,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)

Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,000 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge […] - 2025-06-30 06:44:51

Exelixis (NASDAQ:EXEL) Raised to “Overweight” at Stephens

Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday, Marketbeat Ratings reports. The firm presently has a $60.00 target price on the biotechnology company’s stock, up from their prior target price of $29.00. Stephens’ price […] - 2025-06-26 02:48:49

Exelixis (NASDAQ:EXEL) Shares Gap Up on Analyst Upgrade

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price gapped up prior to trading on Monday after Stephens upgraded the stock from an equal weight rating to an overweight rating. The stock had previously closed at $40.37, but opened at $49.43. Stephens now has a $60.00 price target on the stock, up from their previous […] - 2025-06-25 02:18:52

Exelixis (NASDAQ:EXEL) Reaches New 52-Week High After Analyst Upgrade

Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) reached a new 52-week high during trading on Tuesday after Stephens upgraded the stock from an equal weight rating to an overweight rating. Stephens now has a $60.00 price target on the stock, up from their previous price target of $29.00. Exelixis traded as high as […] - 2025-06-25 02:18:49

Blue Trust Inc. Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Blue Trust Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,976 shares of the biotechnology company’s stock after purchasing an additional 1,745 shares during the period. […] - 2025-06-22 05:22:52

Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 6.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,372 shares of the biotechnology company’s stock after acquiring an additional 307 shares during the quarter. Farther Finance Advisors […] - 2025-06-20 04:26:51

Back to Listing

Disclaimer